ETFS.com

Abiomed Inc.

Exchange: IEX   Type: Common Stock
Price at Close  
 
Change: 
 
Volume: 
 

Not available right now.

× Buy Stock

Remote Buying of Abiomed Inc. through IEX is under development on ETFS.com.

Notify Me when it is ready
× Sell Stock

Remote Selling of Abiomed Inc. through IEX is under development on ETFS.com.

Notify Me when it is ready
Key Statistics
  • Open 
  • Previous Close 
  • Bid 
  • Ask 
  • Day Range -  
  • 52 Week Range -  
  • Volume 
  • Avg. Volume 
  • Volume to USD 
  • Market Cap 
  • Beta 
  • PE Ratio 
  • Latest EPS 
  • EPS TTM 
  • Dividend 
  • Dividend Yield 
  • Ex-Dividend Date 
  • Revenue TTM 
  • Revenue per Share 
  • Revenue per Employee 
  • Profit Margin 
  • Gross Profit TTM 
  • Total Cash TTM 
  • Total Debt TTM 
Share Distribution
  • Shares Outstanding 
  • Float 
  • Short Interest 
  • Short Ratio 
  • Insider Ownership 
  • Institution Ownership 
Abiomed Inc. Performance
Active Alerts for IEX:ABMD
You don't have any alerts set for IEX:ABMD.
About Abiomed Inc.

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.

Real-time ABMD to USD Trade Analysis on IEX
Market Status Premarket

Analysis is available when the exchange & market are open.


×
Create New Alert
First, we need to know what symbol:

Current Quote:Goto Symbol Page
Trigger an Alert when ...

How should we notify you?

This symbol is already on your current watchlist.
Symbol added to your current watchlist!
New alert created!
Saved!
×
Please Verify

needs to be verified before you can use it on ETFS.com.

I have the code already
Enter Verification Code

Enter the code that was sent to you at :

ETFS.com Login to your account:Signup for free!
I forgot my password!
ETFS.com Signup for free:
By joining you agree to our terms.
ETFS.com I forgot my password:
Contact Support
ETFS.com Recovery code (just sent to your email):
Pick a new password: